NCT06908694 Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy
| NCT ID | NCT06908694 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Hamilton Health Sciences Corporation |
| Condition | Prostate Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-07-02 |
| Primary Completion | 2026-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 20 participants in total. It began in 2025-07-02 with a primary completion date of 2026-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
GAIN PC CONTROL is a study investigating Glucagon-Like Peptide-1 Receptor Agonists in men with prostate cancer who are being treated with androgen deprivation therapy.
Eligibility Criteria
Inclusion Criteria: * Have a physician diagnosis of PC * Must be receiving or planned to receive ADT (gonadotropin releasing hormone agonist or antagonist ± androgen receptor pathway inhibitor) * Elevated BMI 1. ≥30kg/m2 or 2. ≥27kg/m2 in the presence of at least one of hypertension, type 2 diabetes, obstructive sleep apnea or dyslipidemia Exclusion Criteria: * Type 1 diabetes * Taking a GLP-1 RA * \<18 years of age * History of pancreatitis * Personal or family history of medullary cancer of the thyroid * Multiple endocrine neoplasia type 2
Contact & Investigator
Darryl Leong, MBBs,MPH,PhD,FRACP,FESC
PRINCIPAL INVESTIGATOR
Population Health Research Institute and McMaster University
Frequently Asked Questions
Who can join the NCT06908694 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06908694 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06908694 currently recruiting?
Yes, NCT06908694 is actively recruiting participants. Contact the research team at sarah.karampatos@phri.ca for enrollment information.
Where is the NCT06908694 trial being conducted?
This trial is being conducted at Hamilton, Canada.
Who is sponsoring the NCT06908694 clinical trial?
NCT06908694 is sponsored by Hamilton Health Sciences Corporation. The principal investigator is Darryl Leong, MBBs,MPH,PhD,FRACP,FESC at Population Health Research Institute and McMaster University. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.